Compare Virgin Galactic Holdings, Inc. (SPCE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs Viatris Inc — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.78 (market cap $329.06M), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 60.1× Virgin Galactic Holdings, Inc.'s market cap, and Viatris Inc pays a 2.83% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| SPCE | VTRS | |
|---|---|---|
Market Cap | $329.06M | $19.79B |
Sector | Industrials | Health |
52-Week High | $7.52 | $17.39 |
52-Week Low | $2.17 | $8.74 |
Enterprise Value | $428.90M | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCE trades at $2.78, up 8.59% in the last session, but remains in a bearish technical trend with negative cash flows and deep losses. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with profitability metrics deeply negative. Recent news highlights volatility tied to space sector sentiment and SpaceX's market activities, contributing to sharp price swings.
The outlook is highly speculative with significant execution and funding risks. While analyst ratings are mixed, the lack of revenue scale and persistent cash burn pose substantial challenges. Investment potential hinges on successful commercialization, but current fundamentals do not support a sustainable valuation, making it suitable only for high-risk investors.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
